替吉奧聯(lián)合奧沙利鉑新輔助化療治療胃癌的臨床效果

蔡蓉　朱志玲

【摘要】 目的：探討替吉奧聯(lián)合奧沙利鉑新輔助化療治療胃癌的臨床效果。方法：選擇筆者所在醫(yī)院2014年5月-2016年5月收治的110例胃癌患者，按照隨機(jī)數(shù)字法將其分為兩組。對(duì)照組患者給予奧沙利鉑+亞葉酸鈣+5-氟尿嘧啶治療，觀察組患者接受替吉奧聯(lián)合奧沙利鉑新輔助化療。觀察兩組患者疾病控制情況，并就兩組患者治療過程中不良反應(yīng)發(fā)生情況展開分析，同時(shí)采用生活質(zhì)量簡(jiǎn)表（SF-36）對(duì)治療前后兩組患者生活質(zhì)量變化情況進(jìn)行評(píng)分。結(jié)果：觀察組患者疾病控制率83.64%，與對(duì)照組的81.82%比較，差異無統(tǒng)計(jì)學(xué)意義（P>0.05）；但觀察組患者不良反應(yīng)發(fā)生率12.73%，低于對(duì)照組的25.45%，差異有統(tǒng)計(jì)學(xué)意義（P<0.05）。兩組患者治療后SF-36評(píng)分顯著優(yōu)于治療前，且觀察組顯著優(yōu)于對(duì)照組，差異有統(tǒng)計(jì)學(xué)意義（P<0.05）。結(jié)論：替吉奧聯(lián)合奧沙利鉑新輔助化療治療胃癌的效果較好，且不良反應(yīng)較少，患者耐受性好，能顯著提高患者生活質(zhì)量，值得推廣。

【關(guān)鍵詞】 胃癌； 替吉奧； 奧沙利鉑； 輔助化療； 不良反應(yīng)

doi：10.14033/j.cnki.cfmr.2017.5.001 文獻(xiàn)標(biāo)識(shí)碼 A 文章編號(hào) 1674-6805（2017）05-0001-02

The Clinical Effect of S-1 Combined with Oxaliplatin Neoadjuvant Chemotherapy for Gastric Cancer/CAI Rong，ZHU Zhi-ling.//Chinese and Foreign Medical Research，2017，15（5）：1-2

【Abstract】 Objective：To investigate the clinical effect of S-1 combined with Oxaliplatin neoadjuvant chemotherapy for gastric cancer.Method：From May 2014 to May 2016，110 cases of gastric cancer patients who admitted to our hospital were selected and divided into two groups according to the random number method.The control group was treated with Oxaliplatin，Calcium Folinate and 5-Fluorouracil treatment，the observation group patients received neoadjuvant chemotherapy with S-1 combined with Oxaliplatin.The disease control and the adverse reactions of the two groups of patients in the process of occurrence were analyzed，and the quality of life scale（SF-36） score of two groups before and after treatment changes in life quality was compared.Result：The disease control rate was 83.64% and 81.82% in the control group and the observation group，there was no significant difference in two groups（P>0.05），but the occurrence of adverse reactions of patients 12.73% in the observation group was obviously lower than 25.45% in the control group，the difference was statistically significant（P<0.05）.After treatment，the SF-36 score of the two groups was significantly better than before treatment，and the observation group was significantly better than the control group，the difference was statistically significant（P<0.05）.Conclusion：The effect of S-1 combined with Oxaliplatin neoadjuvant chemotherapy for gastric cancer treatment is good，and less adverse reactions，with good tolerance，can significantly improve the quality of life of patients，worthy of promotion.

【Key words】 Gastric cancer； S-1； Oxaliplatin； Adjuvant chemotherapy； Adverse reaction

First-authors address：The Fifth Hospital Affiliated to Zhongshan University，Zhuhai 519000，China

胃癌是臨床上常見的惡性腫瘤，發(fā)病率較高，受到地域因素、飲食生活、細(xì)菌感染、癌前病變等多個(gè)因素治療，患者表現(xiàn)為惡心、嘔吐等類似潰瘍病的上消化道癥狀，嚴(yán)重影響著患者的生活質(zhì)量。化療是臨床上針對(duì)行根治性手術(shù)和晚期胃癌患者的有效治療手段，但不同的化療方案對(duì)患者的影響不同[1]。本次研究以筆者所在醫(yī)院兩年間收治的110例患者為例，分為兩組行不同的化療方案治療，現(xiàn)報(bào)道如下。

1 資料與方法

1.1 一般資料

以筆者所在醫(yī)院2014年5月-2016年5月收治的110例胃癌患者為例，所有患者入院后均接受了X線鋇餐檢查、腹部超聲、CT及電子發(fā)射成像檢查確診。按照隨機(jī)數(shù)字法將其分為兩組，每組55例。對(duì)照組55例患者中男27例，女28例，年齡64～78歲，平均（70.3±14.0）歲，觀察組55例患者中男29例，女26例，年齡65～76歲，平均（71.2±15.0）歲。排……